Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) Net Margin (2020 - 2023)

Historic Net Margin for Gain Therapeutics (GANX) over the last 4 years, with Q1 2023 value amounting to 9310.11%.

  • Gain Therapeutics' Net Margin fell 20385400.0% to 9310.11% in Q1 2023 from the same period last year, while for Dec 2023 it was 40878.89%, marking a year-over-year decrease of 283237600.0%. This contributed to the annual value of 40878.89% for FY2023, which is 283237600.0% down from last year.
  • As of Q1 2023, Gain Therapeutics' Net Margin stood at 9310.11%, which was down 20385400.0% from 5347.33% recorded in Q2 2022.
  • Over the past 5 years, Gain Therapeutics' Net Margin peaked at 3988.53% during Q2 2021, and registered a low of 46506.87% during Q1 2021.
  • Over the past 4 years, Gain Therapeutics' median Net Margin value was 8755.7% (recorded in 2020), while the average stood at 13108.43%.
  • In the last 5 years, Gain Therapeutics' Net Margin tumbled by -377511700bps in 2021 and then skyrocketed by 392353000bps in 2022.
  • Gain Therapeutics' Net Margin (Quarter) stood at 18116.65% in 2020, then skyrocketed by 59bps to 7452.17% in 2021, then grew by 28bps to 5347.33% in 2022, then tumbled by -74bps to 9310.11% in 2023.
  • Its Net Margin was 9310.11% in Q1 2023, compared to 5347.33% in Q2 2022 and 7271.57% in Q1 2022.